Written and reviewed by the OptiBliss Optimal Practitioner Team — integrative nurse practitioners and functional-medicine clinicians.
If GLP-1 drugs were generation one and dual agonists were generation two, retatrutide — sold in the research space as “GLP-3 RT” — is the molecule everyone’s watching for generation three. The science is genuinely interesting. The important caveats are just as real. This is educational, and this product is a research-use-only compound, not an approved medicine.
What it is
“GLP-3 RT” is a research-peptide name for retatrutide. There isn’t actually a hormone called GLP-3 — the label is marketing shorthand for what makes retatrutide notable: it’s a triple receptor agonist, engaging GIP, GLP-1, and glucagon receptors at once. It’s currently an investigational drug candidate in clinical trials, and the listing discussed here is sold for laboratory research only.
How it works (the incretin science)
Where single GLP-1 agonists hit one receptor and tirzepatide hits two, retatrutide adds a third: glucagon-receptor activity. In research, that glucagon component is of interest because of its role in energy expenditure and metabolism, layered on top of the glucose- and appetite-related effects of the GLP-1 and GIP pathways. It’s the most ambitious incretin design studied to date.
What researchers study it for
Retatrutide has been studied in clinical research for glucose regulation, metabolic function, and body-weight outcomes. That describes the investigational drug program — not this research-use-only listing, and not a suggestion of personal use. A promising trial molecule is still a trial molecule.
Where the science stands
Retatrutide is investigational — it is not yet an approved medicine anywhere, which makes it a step earlier than even tirzepatide. Early trial data has drawn a lot of attention, but “promising in trials” is a long way from “approved, dosed, and monitored.” As a research compound sold outside the pharmacy system, identity, purity, and quality are not guaranteed, which is precisely why clinician oversight matters here.
Regulatory & safety context
This listing is for research use only — not for human or veterinary use — and retatrutide is not FDA-approved. If you’re interested in the metabolic outcomes this class is studied for, the responsible route is a conversation with a qualified clinician about approved, supervised options, not a research vial.
FAQ
Is there really a “GLP-3”?
No — it’s marketing shorthand. Retatrutide is a triple agonist (GIP + GLP-1 + glucagon); “GLP-3” just gestures at it being the next step beyond dual agonists.
How is it different from tirzepatide?
Tirzepatide hits two receptors; retatrutide adds glucagon-receptor activity as a third.
Is it approved?
No. It is an investigational compound in clinical research and is designated research use only as sold here.
The OptiBliss Optimal Practitioner Team formulates and reviews all of our content and products. Have a question? Book a consult with our team.
This article is educational commentary. The peptide discussed is designated for research use only, is not FDA-approved for the treatment of any condition, and nothing here is medical advice or a recommendation for human use.